Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure.

Vucic, RM; Andrejic, OM; Stokanovic, D; Stoimenov, TJ; McClements, L; Nikolic, VN; Sreckovic, M; Veselinovic, M; Aleksandric, S; Popadic, V; Zdravkovic, M; Pavlovic, M

Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure.

Vucic, RM Andrejic, OM Stokanovic, D Stoimenov, TJ McClements, L

Nikolic, VN Sreckovic, M Veselinovic, M Aleksandric, S Popadic, V Zdravkovic, M Pavlovic, M

Permalink

Publisher:: MDPI
Publication Type:: Journal Article
Citation:: Diagnostics (Basel), 2023, 13, (21), pp. 3348
Issue Date:: 2023-10-31

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (681.12 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Vucic, RM
dc.contributor.author	Andrejic, OM
dc.contributor.author	Stokanovic, D
dc.contributor.author	Stoimenov, TJ
dc.contributor.author	McClements, L https://orcid.org/0000-0002-4911-1014
dc.contributor.author	Nikolic, VN
dc.contributor.author	Sreckovic, M
dc.contributor.author	Veselinovic, M
dc.contributor.author	Aleksandric, S
dc.contributor.author	Popadic, V
dc.contributor.author	Zdravkovic, M
dc.contributor.author	Pavlovic, M
dc.date.accessioned	2024-02-07T07:31:04Z
dc.date.available	2023-10-24
dc.date.available	2024-02-07T07:31:04Z
dc.date.issued	2023-10-31
dc.identifier.citation	Diagnostics (Basel), 2023, 13, (21), pp. 3348
dc.identifier.issn	2075-4418
dc.identifier.issn	2075-4418
dc.identifier.uri	http://hdl.handle.net/10453/175440
dc.description.abstract	BACKGROUND: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and quality of life. METHODS: Our study included 59 patients with AMI and a preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 h of chest pain onset from the aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACEs) were evaluated at six months follow-up. RESULTS: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from the aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011-1.491; p = 0.038; OR 3.438; 95%CI: 1.275-9.265; p = 0.015). ROC analysis identifies the Gal-3 plasma concentration from the aortic root as a better predictor of MACE or death (cut-off ≥ 10.86 ng/mL; AUC 0.858; 95%CI: 0.744-0.973; p < 0.001) than Gal-3 plasma concentration from the femoral/radial artery (cut-off ≥ 10.18 ng/mL; AUC 0.742; 95%CI: 0.596-0.888; p = 0.006). CONCLUSION: the Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 h after chest pain onset is a valuable biomarker of prognosis at six months follow-up.
dc.format	Electronic
dc.language	eng
dc.publisher	MDPI
dc.relation.ispartof	Diagnostics (Basel)
dc.relation.isbasedon	10.3390/diagnostics13213348
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	3202 Clinical sciences
dc.title	Galectin-3 as a Prognostic Biomarker in Patients with First Acute Myocardial Infarction without Heart Failure.
dc.type	Journal Article
utslib.citation.volume	13
utslib.location.activity	Switzerland
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
pubs.organisational-group	University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
dc.date.updated	2024-02-07T07:31:00Z
pubs.issue	21
pubs.publication-status	Published online
pubs.volume	13
utslib.citation.issue	21

Abstract:

BACKGROUND: Galectin-3 (Gal-3) is a biomarker involved in a wide range of diseases including cardiac remodeling following acute myocardial infarction (AMI). Identification of prognostic markers in patients with AMI can guide strategies towards improved survival and quality of life. METHODS: Our study included 59 patients with AMI and a preserved ejection fraction. We determined the Gal-3 plasma concentration within 24 h of chest pain onset from the aortic root, femoral/radial artery, coronary sinus and cubital vein. Major adverse cardiovascular events (MACEs) were evaluated at six months follow-up. RESULTS: MACE at six months post-AMI was recorded in 20 patients (34%). The Gal-3 plasma concentration from the aortic root and the femoral/radial artery were independent predictors of MACE at six months follow-up after the first AMI (OR 1.228; 95%CI: 1.011-1.491; p = 0.038; OR 3.438; 95%CI: 1.275-9.265; p = 0.015). ROC analysis identifies the Gal-3 plasma concentration from the aortic root as a better predictor of MACE or death (cut-off ≥ 10.86 ng/mL; AUC 0.858; 95%CI: 0.744-0.973; p < 0.001) than Gal-3 plasma concentration from the femoral/radial artery (cut-off ≥ 10.18 ng/mL; AUC 0.742; 95%CI: 0.596-0.888; p = 0.006). CONCLUSION: the Gal-3 plasma concentration in patients with AMI determined during coronary angiography, especially from the aortic root, within 24 h after chest pain onset is a valuable biomarker of prognosis at six months follow-up.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/175440